Evidence MDRP Risks Gaps Tasks Reports
Explore Search
Task Contracted Study CM Validation II (Cross Risk)
Last Published:  03/26/21 03:34:00 PM (Central)
Task Book: Entry Unavailable
Principal Investigator: TBD
Short Title: CM Validation II
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Solicited
Aims:

Studies to validate identified medical countermeasures that address multiple tumor types and multiple risk areas (i.e., cancer, late neurodegeneration, cardiovascular disease) with the following aims:

 

Specific Aims:

  • Aim 1 (Cross Risk): Validate efficacy of candidate countermeasure agents in additional model systems in compliance with FDA animal rules.

  • Aim 2 (Cross Risk): Validate efficacy of candidate countermeasure agents in space relevant environment.

  • Aim 3 (Cross Risk):  Determine minimum dosing (mg/day) requirements for optimum effectiveness.

  • Aim 4 (Cross Risk):  Evaluate any potential antagonistic effects across space radiation risk area endpoints including multiple tumor types

  • Aim 5 (Cross Risk): Evaluate biomarker approaches to assess countermeasure efficacy for surveillance, treatment, and outcome prediction.


Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here!TaskContracted Study CM Validation II (Cross Risk)
RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
GapBMed-102: Given exposures to spaceflight hazards (space radiation, isolation), how do we identify individual susceptibility, monitor molecular/biomarkers and acceptable thresholds, and validate behavioral health and CNS/neurological/neuropsychological performance measures and domains of relevance to exploration class missions?
GapBMed-103: What are the validated, efficacious treatments (individual or Team-based) and/or countermeasures to prevent adverse behavioral conditions, CNS/neurological, and/or psychiatric disorders caused by either single and/or integrated exposures to spaceflight hazards during exploration class missions?
GapBMed-104: Given the potentially negative spaceflight associated CNS changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated modifications to habitat/vehicle to mitigate stressors impacting on CNS / cognition / behavioral health?
GapBMed-105: Given the potentially negative spaceflight associated CNS/cognitive changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated medical or dietary countermeasures to mitigate stressors impacting on CNS / cognition / behavioral health?
You are here!TaskContracted Study CM Validation II (Cross Risk)
RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
You are here!TaskContracted Study CM Validation II (Cross Risk)
RiskRisk of Radiation Carcinogenesis
You are here!TaskContracted Study CM Validation II (Cross Risk)
RiskRisk of Spaceflight Induced Cardiovascular Disease
You are here!TaskContracted Study CM Validation II (Cross Risk)